Charter Oak Capital Management’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Charter Oak Capital Management’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-80	Closed	-$11K	–	397
2022 Q2	$11K	Sell	80 -30	-27%	-$4.13K	﹤0.01%	576
2022 Q1	$16K	Sell	110 -30	-21%	-$4.44K	﹤0.01%	552
2021 Q4	$23K	Hold	140	–	–	﹤0.01%	475
2021 Q3	$23K	Sell	140 -20	-13%	-$3.42K	﹤0.01%	437
2021 Q2	$28K	Hold	160	–	–	﹤0.01%	395
2021 Q1	$26K	Hold	160	–	–	﹤0.01%	398
2020 Q4	$27K	Buy	+160	New	+$26K	﹤0.01%	375

Other funds holding FBT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SOS

Silver Oak Securities Jackson, Tennessee $1.37B AUM 20.67% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BFG

Berger Financial Group Plymouth, Minnesota $1.79B AUM 15.72% 1-Year Est. Return

Charter Oak Capital Management's FBT Position: Q3 2022 in Review

Charter Oak Capital Management sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q3 2022, closing a stake of 80 shares — an estimated $11K sold.

Charter Oak Capital Management first reported a position in FBT in Q4 2020 and held it in 7 quarters. The position peaked at $28K in Q2 2021. 218 funds tracked by Wall St. Rank hold FBT as of Q3 2022.

Charter Oak Capital Management reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 80 First Trust NYSE Arca Biotechnology Index Fund shares in Q3 2022, an estimated $11K.
Charter Oak Capital Management first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2020 and held it in 7 quarters.
Charter Oak Capital Management's First Trust NYSE Arca Biotechnology Index Fund position peaked at $28K in Q2 2021.
218 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.